Related Experiment Video
Updated: May 13, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Left atrial appendage occlusion for recurrent stroke while on oral anticoagulation: a case series
Gonçalo Costa1,2, Mafalda Griné1, Mariana Simões1
1Serviço de Cardiologia, Centro Hospitalar e Universitário de Coimbra, Praceta Professor Mota Pinto, 3004-561 Coimbra, Portugal.
Insights
For patients with atrial fibrillation experiencing recurrent strokes despite oral anticoagulation, left atrial appendage occlusion (LAAO) may offer additional protection. This case series explores LAAO as an adjunctive therapy for stroke prevention in challenging AF cases.
Area of Science:
- Cardiology
- Neurology
- Interventional Cardiology
Background:
- Oral anticoagulation (OAC) is recommended for stroke prevention in atrial fibrillation (AF).
- Recurrent thrombo-embolic events occur in some AF patients despite adequate OAC.
- Optimal management for these cases remains unclear, leading to varied clinical practices.
Observation:
- A case series of three AF patients with recurrent thrombo-embolic events despite adequate OAC.
- Patients underwent left atrial appendage occlusion (LAAO) as an adjunctive stroke prevention strategy.
- Outcomes varied, with some patients experiencing complications during LAAO but ultimately remaining event-free.
Findings:
- Left atrial appendage occlusion (LAAO) can be a viable adjunctive strategy for stroke prevention in AF patients with recurrent events.
- Individualized treatment approaches are crucial for managing complex AF cases.
- Successful LAAO was observed in two cases, with one patient experiencing complications but remaining event-free post-discharge.
Implications:
- LAAO may provide additional stroke protection for AF patients unresponsive to OAC.
- Further randomized controlled trials are necessary to establish the efficacy and safety of LAAO in this population.
- These cases contribute to understanding the potential role of LAAO in secondary stroke prevention for high-risk AF patients.
Background:
Clinical practice guidelines recommend oral anticoagulation (OAC) for stroke prevention in selected patients with atrial fibrillation (AF). However, some patients still experience thrombo-embolic events despite adequate anticoagulation. The optimal management of these cases remains uncertain, leading to practice pattern variability. We present a series of three cases illustrating the use of left atrial appendage occlusion (LAAO) as an adjunctive stroke prevention strategy in AF patients with recurrent thrombo-embolic events despite adequate anticoagulation.
Case Summary:
Case one describes an 89-year-old female on apixaban who presented with a thrombus and underwent successful mechanical thrombectomy. Left atrial appendage occlusion was performed, and no subsequent thrombo-embolic events were reported. Case 2 involves a 72-year-old female on full-dose apixaban who experienced recurrent strokes despite adequate anticoagulation. Thrombectomy was performed twice, and complications arose during LAAO. The patient was discharged on warfarin + clopidogrel and remained event-free at the six-month follow-up. Case 3 features an 88-year-old female on rivaroxaban who experienced recurrent cerebral ischaemic events and gastrointestinal bleeding. Left atrial appendage occlusion using an Amplatzer Amulet™ device was successful, and the patient remained event-free at the one-year follow-up.
Discussion:
This case series emphasizes the complexity of stroke prevention in AF patients and underscores the need for an individualized approach. Incorporating LAAO alongside OAC can provide additional stroke protection for patients with inadequate response to anticoagulation. Further randomized controlled trials are needed to evaluate the efficacy and safety of this approach. In light of the limited evidence available, these cases contribute to the growing body of knowledge on the potential role of LAAO in secondary stroke prevention in AF patients with recurrent thrombo-embolic events despite appropriate anticoagulation.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care
Ischemic Stroke l: Introduction
Hemorrhagic Stroke l: Introduction
Hemorrhagic Stroke ll: Pathophysiology

